Haralampos M Moutsopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8754468/publications.pdf

Version: 2024-02-01

276 papers

25,736 citations

76 h-index

9428

⁷⁸³⁶ 155

281 all docs

281 does citations

times ranked

281

13120 citing authors

g-index

#	Article	IF	CITATIONS
1	Subclinical atherosclerosis profiles in rheumatoid arthritis and primary Sjögren's syndrome: the impact of <i>BAFF</i> genetic variations. Rheumatology, 2023, 62, 958-968.	0.9	2
2	Genetic Variants of the BAFF Gene and Risk of Fatigue Among Patients With Primary Sjögren's Syndrome. Frontiers in Immunology, 2022, 13, 836824.	2.2	5
3	Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies. Frontiers in Endocrinology, 2022, 13, 860880.	1.5	5
4	COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2022, 131, 102846.	3.0	6
5	Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. Clinical Immunology, 2021, 223, 108649.	1.4	9
6	Medical education in Greece: Necessary reforms need to be re-considered. Medical Teacher, 2021, 43, 287-292.	1.0	0
7	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogren's Syndrome. Journal of Clinical Medicine, 2021, 10, 644.	1.0	7
8	Arrhythmias and Conduction Disturbances in Autoimmune Rheumatic Disorders. Arrhythmia and Electrophysiology Review, 2021, 10, 17-25.	1.3	11
9	POS0290 PREDICTING RISK FACTORS OF MALT LYMPHOMA IN SJÃ−GREN'S SYNDROME. Annals of the Rheumatic Diseases, 2021, 80, 370.1-371.	0.5	0
10	OP0294â€SJÃ-GREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURV Annals of the Rheumatic Diseases, 2021, 80, 180-181.	/IVAL. 0.5	0
11	OP0291â€SEVERITY OF LABIAL MINOR SALIVARY GLAND FOCUS SCORE AND FUTURE LYMPHOMA DEVELOPME IN SJÖGREN'S SYNDROME. Annals of the Rheumatic Diseases, 2021, 80, 178.2-179.	ENT 0.5	0
12	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?. Frontiers in Immunology, 2021, 12, 683623.	2.2	6
13	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648.	3.0	24
14	A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine. Journal of Autoimmunity, 2021, 121, 102649.	3.0	18
15	Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk. Journal of Autoimmunity, 2021, 122, 102675.	3.0	4
16	+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren's Syndrome: Potential Clinical and Pathogenetic Implications. Journal of Clinical Medicine, 2021, 10, 3960.	1.0	5
17	Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in Sjögren's syndrome. Journal of Autoimmunity, 2021, 123, 102704.	3.0	9
18	COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. Journal of Autoimmunity, 2021, 123, 102687.	3.0	19

#	Article	IF	CITATIONS
19	Autoimmune rheumatic diseases: One or many diseases?. Journal of Translational Autoimmunity, 2021, 4, 100129.	2.0	15
20	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2021, 125, 102743.	3.0	45
21	Systemic Lupus Erythematosus, Mixed Connective Tissue Disease and Antiphospholipid Syndrome. , 2021, , 77-93.		1
22	Sjögren's Syndrome, IgG4-Related Disorders. , 2021, , 107-119.		0
23	COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers. Mediterranean Journal of Rheumatology, 2021, 32, 188.	0.3	2
24	An unusual presentation of giant cell arteritis in a middle-aged woman. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 187-188.	0.4	0
25	Combined seronegativity in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
26	An unusual presentation of giant cell arteritis in a middle-aged woman. Clinical and Experimental Rheumatology, 2021, 39, 187-188.	0.4	0
27	Combined seronegativity in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 80-84.	0.4	8
28	Drs. Mavragani and Moutsopoulos reply. Journal of Rheumatology, 2020, 47, 158.2-158.	1.0	0
29	Sjögren's syndrome: Old and new therapeutic targets. Journal of Autoimmunity, 2020, 110, 102364.	3.0	79
30	Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity. European Journal of Clinical Investigation, 2020, 50, e13195.	1.7	28
31	Cryoglobulinemic vasculitis in primary Sjögren's Syndrome: Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease. Seminars in Arthritis and Rheumatism, 2020, 50, 846-853.	1.6	28
32	Atherosclerosis in SLE: a potential role for serum parathormone levels. Lupus Science and Medicine, 2020, 7, e000393.	1.1	10
33	Correspondence on â€Jan Gösta Waldenström and rheumatology'. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219508.	0.5	2
34	Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Annals of the Rheumatic Diseases, 2020, 79, 1253-1254.	0.5	22
35	Sicca syndrome following immune checkpoint inhibition. Clinical Immunology, 2020, 217, 108497.	1.4	12
36	Clinical Significance of Higher Cutoffs for Myositis Autoantibody Positivity Using the Euroimmun Research Line Blot: Comment on the Article by Mecoli et al. Arthritis and Rheumatology, 2020, 72, 1042-1044.	2.9	5

#	Article	IF	CITATIONS
37	Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 134-141.	0.4	6
38	Primary versus Secondary Sj \tilde{A} ¶gren Syndrome: Is It Time To Reconsider These Terms?. Journal of Rheumatology, 2019, 46, 665-666.	1.0	38
39	West Nile Virus infection triggering autoimmune encephalitis: Pathophysiological and therapeutic implications. Clinical Immunology, 2019, 207, 97-99.	1.4	20
40	Mentoring in medicine. European Journal of Clinical Investigation, 2019, 49, e13126.	1.7	3
41	Rheumatology in Greece: pros and cons. Mediterranean Journal of Rheumatology, 2019, 31, 8.	0.3	1
42	Evolution of one systemic rheumatic disease into another: scleroderma evolving to eosinophilic fasciitis with myositis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 149-150.	0.4	2
43	Sjögren's Syndrome, IgG4-Related Disorders. , 2018, , 79-87.		0
44	Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. Clinical Immunology, 2018, 193, 110-117.	1.4	25
45	The oral mucosa: A barrier site participating in tissueâ€specific and systemic immunity. Oral Diseases, 2018, 24, 22-25.	1.5	31
46	Evolution from one autoimmune disorder to another. Epitope spreading?. Scandinavian Journal of Immunology, 2018, 87, e12657.	1.3	1
47	Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study. Clinical Rheumatology, 2018, 37, 737-747.	1.0	29
48	B-cell activating factor and related genetic variants in lupus related atherosclerosis. Journal of Autoimmunity, 2018, 92, 87-92.	3.0	51
49	Tongue Atrophy in Sjögren Syndrome Patients with Mucosa-associated Lymphoid Tissue Lymphoma: Autoimmune Epithelitis beyond the Epithelial Cells of Salivary Glands?. Journal of Rheumatology, 2018, 45, 1565-1571.	1.0	11
50	Pauci-immune crescentic glomerulonephritis in a patient with B-lymphocyte poly/autoreactivity. Clinical and Experimental Rheumatology, 2018, 36, 344.	0.4	0
51	Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 94-101.	0.4	14
52	Sjögren's syndrome: disease activity indexes! Do they make us better clinicians or technicians?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 29-30.	0.4	0
53	Severe cutaneous hand infection: Mycobacterium marinum in an immunosuppressed patient. Clinical and Experimental Rheumatology, 2018, 36, 1117.	0.4	2
54	Autoantibodies to ox-LDL in Sj \tilde{A} ¶gren's syndrome: are they atheroprotective?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 61-67.	0.4	5

#	Article	IF	Citations
55	Analysis of NLRP3, MVK and TNFRSF1A variants in adult Greek patients with autoinflammatory symptoms. Clinical and Experimental Rheumatology, 2018, 36, 86-89.	0.4	9
56	lgG4â€related sialadenitis and Sjögren's syndrome. Oral Diseases, 2017, 23, 152-156.	1.5	50
57	A comprehensive evaluation for the treatment of lupus nephritis. Journal of Autoimmunity, 2017, 78, 1-10.	3.0	31
58	07.13â€A case of sting-associated vasculopathy with onset in infancy (savi) in a young adult male with a novel tmem173 gene mutation., 2017,,.		0
59	Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome. Clinical Immunology, 2017, 183, 300-303.	1.4	21
60	Type I interferonopathy in a young adult. Rheumatology, 2017, 56, 2241-2243.	0.9	17
61	07.11â€Contribution of mthfr gene variants in lupus related subclinical atherosclerosis. , 2017, , .		0
62	MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. Scientific Reports, 2017, 7, 7354.	1.6	28
63	07.08â€Contribution of mthfr gene polymorphisms in primary sjögren's syndrome related lymphomagenesis. , 2017, , .		0
64	Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Frontiers in Psychiatry, 2017, 8, 286.	1.3	6
65	Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study. Clinical and Experimental Rheumatology, 2017, 35, 192-200.	0.4	4
66	Rapidly progressive lung disease in a patient with signs of clinically amyopathic dermatomyositis. Clinical and Experimental Rheumatology, 2017, 35, 1057-1058.	0.4	0
67	Analysis of the cell populations composing the mononuclear cell infiltrates in the labial minor salivary glands from patients with rheumatoid arthritis and sicca syndrome. Journal of Autoimmunity, 2016, 73, 85-91.	3.0	12
68	Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease. Arthritis and Rheumatology, 2016, 68, 2686-2696.	2.9	149
69	Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis. Journal of Autoimmunity, 2016, 72, 57-64.	3.0	6
70	lgG4â€Related Orbital Disease Presenting With Unilateral Eyelid Swelling. Arthritis and Rheumatology, 2016, 68, 2824-2824.	2.9	4
71	Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores. Clinical Immunology, 2016, 173, 157-160.	1.4	24
72	Predicting the risk for lymphoma development in Sjogren syndrome. Medicine (United States), 2016, 95, e3766.	0.4	137

#	Article	IF	Citations
73	Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases. Arthritis and Rheumatology, 2016, 68, 1677-1687.	2.9	94
74	Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations. Lupus, 2016, 25, 1260-1265.	0.8	14
75	A BAFF Receptor His159Tyr Mutation in Sjögren's Syndrome–Related Lymphoproliferation. Arthritis and Rheumatology, 2015, 67, 2732-2741.	2.9	60
76	Sjögren's Syndrome. , 2015, , 883-889.		0
77	Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. Arthritis Research and Therapy, 2015, 17, 99.	1.6	64
78	Sjögren's Syndrome. , 2015, , 419-428.		0
79	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. PLoS ONE, 2015, 10, e0116189.	1.1	77
80	Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. Journal of Autoimmunity, 2015, 65, 30-37.	3.0	39
81	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. Journal of Neuroimmunology, 2015, 289, 8-11.	1.1	30
82	Impaired degradation and aberrant phagocytosis of necrotic cell debris in the peripheral blood of patients with primary Sjögren's syndrome. Journal of Autoimmunity, 2015, 56, 12-22.	3.0	19
83	Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clinical and Experimental Rheumatology, 2015, 33, 216-24.	0.4	32
84	Impaired Clearance of Early Apoptotic Cells Mediated by Inhibitory IgG Antibodies in Patients with Primary Sjögren's Syndrome. PLoS ONE, 2014, 9, e112100.	1.1	23
85	Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome. Genes and Immunity, 2014, 15, 54-56.	2.2	5
86	Elevated IgG4 Serum Levels Among Primary Sjögren's Syndrome Patients: Do They Unmask Underlying IgG4â€Related Disease?. Arthritis Care and Research, 2014, 66, 773-777.	1.5	42
87	Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study. Journal of the Neurological Sciences, 2014, 347, 143-147.	0.3	76
88	Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: A 10-year follow-up study. Seminars in Arthritis and Rheumatism, 2014, 43, 558-565.	1.6	36
89	Sjögren's Syndrome. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 273-285.	9.6	198
90	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. Journal of Autoimmunity, 2014, 51, 89-98.	3.0	99

#	Article	IF	CITATIONS
91	Sjögren's syndrome: A forty-year scientific journey. Journal of Autoimmunity, 2014, 51, 1-9.	3.0	61
92	Sjögren's Syndrome. , 2014, , 495-510.		3
93	Classification criteria of Sjögren's syndrome. Journal of Autoimmunity, 2014, 48-49, 42-45.	3.0	58
94	Sjögren syndrome. Cmaj, 2014, 186, E579-E586.	0.9	135
95	Treatment of dry eyes in Sj $ ilde{A}$ gren's syndrome: the role of autologous blood serum. Expert Opinion on Orphan Drugs, 2013, 1, 445-456.	0.5	1
96	Minor Salivary Gland Inflammatory Lesions in Sj $\tilde{A}\P$ gren Syndrome: Do They Evolve?. Journal of Rheumatology, 2013, 40, 1566-1571.	1.0	62
97	Sjögren's syndrome. International Journal of Clinical Rheumatology, 2013, 8, 517-520.	0.3	1
98	Clinically Significant Renal Involvement in Primary Sj \tilde{A} ¶gren's Syndrome: Clinical Presentation and Outcome. Arthritis and Rheumatism, 2013, 65, 2945-2953.	6.7	129
99	New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. Current Opinion in Rheumatology, 2013, 25, 623-629.	2.0	48
100	OP0083â€RO52/TRIM21 Expression in Salivary Gland Epithelial Cells (SGECS) is Upregulated by TLR3-Signaling. Annals of the Rheumatic Diseases, 2013, 72, A78.2-A78.	0.5	0
101	OP0079â€Salivary Gland Epithelial Cells (SGECS) Promote the Differentiation of B Cells. Annals of the Rheumatic Diseases, 2013, 72, A77.1-A77.	0.5	3
102	THU0137â€Effectiveness and Adverse Reactions of Long-Term Use of Biologic Agents in Patients with Rheumatoid Arthritis: A Retrospective Study. Annals of the Rheumatic Diseases, 2013, 72, A209.1-A209.	0.5	1
103	Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome. Medicine (United) Tj ETQq1 I	l 0.78431 0.4	4 rgBT /Ove 194
104	Morbidity, Mortality, and Organ Damage in Patients with Antiphospholipid Syndrome. Journal of Rheumatology, 2012, 39, 516-523.	1.0	54
105	Brief Report: Adrenal autoimmunity in primary Sjögren's syndrome. Arthritis and Rheumatism, 2012, 64, 4066-4071.	6.7	16
106	The salivary gland epithelial cells of patients with primary Sjögren's syndrome manifest significantly reduced responsiveness to 17β-estradiol. Journal of Autoimmunity, 2012, 39, 64-68.	3.0	28
107	Endocrine alterations in primary Sjogren's syndrome: An overview. Journal of Autoimmunity, 2012, 39, 354-358.	3.0	64
108	Pathogenesis of Sjögren's syndrome: What we know and what we should learn. Journal of Autoimmunity, 2012, 39, 4-8.	3.0	191

#	Article	IF	Citations
109	Peripheral neuropathies in Sjögren's syndrome: A critical update on clinical features and pathogenetic mechanisms. Journal of Autoimmunity, 2012, 39, 27-33.	3.0	142
110	Is Sjögren's syndrome a retroviral disease?. Arthritis Research and Therapy, 2011, 13, 212.	1.6	36
111	Peripheral neuropathies in Sjogren syndrome: a new reappraisal. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 798-802.	0.9	73
112	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β ₂ â€glycoprotein I. Arthritis and Rheumatism, 2011, 63, 2774-2782.	6.7	96
113	Etiology and Pathogenesis of Sjögren's Syndrome with Special Emphasis on the Salivary Glands. , 2011, , 243-267.		1
114	Treatment of B-Cell Lymphoma. , 2011, , 547-563.		0
115	Sjögren syndrome. , 2011, , 1339-1350.e1.		1
116	\hat{l}^2 2 Glycoprotein I (\hat{l}^2 2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood, 2010, 115, 713-723.	0.6	92
117	The geoepidemiology of Sjögren's syndrome. Autoimmunity Reviews, 2010, 9, A305-A310.	2.5	246
118	Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. European Respiratory Journal, 2010, 36, 116-121.	3.1	134
119	Psychopathological and personality features in primary Sjogren's syndrome-associations with autoantibodies to neuropeptides. Rheumatology, 2010, 49, 1762-1769.	0.9	43
120	Characteristics of the minor salivary gland infiltrates in SjÃ \P gren's syndrome. Journal of Autoimmunity, 2010, 34, 400-407.	3.0	339
121	Anticentromere antibody positive Sj \tilde{A} ¶gren's Syndrome: a retrospective descriptive analysis. Arthritis Research and Therapy, 2010, 12, R47.	1.6	67
122	Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyalgia Syndrome. Journal of Rheumatology, 2009, 36, 1626-1630.	1.0	17
123	Stress, coping strategies and social support in patients with primary Sjögren's syndrome prior to disease onset: a retrospective case–control study. Annals of the Rheumatic Diseases, 2009, 68, 40-46.	0.5	50
124	Hematologic Manifestations and Predictors of Lymphoma Development in Primary Sjögren Syndrome. Medicine (United States), 2009, 88, 284-293.	0.4	233
125	Monoclonal process in primary Sjögren's syndrome and cross-reactive idiotype associated with rheumatoid factor. Clinical and Experimental Immunology, 2008, 82, 509-514.	1.1	19
126	Mucosa-Associated Lymphoid Tissue Lymphoma in Sjögren's Syndrome: Risks, Management, and Prognosis. Rheumatic Disease Clinics of North America, 2008, 34, 921-933.	0.8	69

#	Article	IF	CITATIONS
127	Is mizoribine a new therapeutic agent for Sj $ ilde{A}$ gren's syndrome?. Nature Clinical Practice Rheumatology, 2008, 4, 350-351.	3.2	8
128	Sjögren Syndrome., 2008,, 37-42.		1
129	Cardiac Magnetic Resonance Imaging Detects Long-Term Fibrotic Changes in Patients with Primary Eosinophilic Disorders: A Cross-Sectional Study. Blood, 2008, 112, 5236-5236.	0.6	0
130	Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren's syndrome. Journal of Rheumatology, 2008, 35, 2012-6.	1.0	50
131	Mortality in SjĶgren's syndrome. Clinical and Experimental Rheumatology, 2008, 26, S66-71.	0.4	40
132	Sjögren's Syndrome. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 459-471.	0.8	49
133	Rates of infiltration by macrophages and dendritic cells and expression of interleukinâ€18 and interleukinâ€12 in the chronic inflammatory lesions of Sjögren's syndrome: Correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis and Rheumatism, 2007, 56, 3977-3988.	6.7	167
134	Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary SjĶgren's syndrome. Clinical and Experimental Immunology, 2007, 147, 497-503.	1.1	163
135	Analysis of parotid glands of primary Sj \tilde{A} gren's syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets. Clinical and Experimental Immunology, 2007, 147, 81-89.	1.1	25
136	Persistent Viral Infection in Primary Sjogren's Syndrome: Review and Perspectives. Clinical Reviews in Allergy and Immunology, 2007, 32, 210-214.	2.9	45
137	Conventional Therapy of Sjogren's Syndrome. Clinical Reviews in Allergy and Immunology, 2007, 32, 284-291.	2.9	61
138	Sjögren's Syndrome or Autoimmune Epithelitis?. Clinical Reviews in Allergy and Immunology, 2007, 32, 199-200.	2.9	21
139	Osteoarticular Manifestations of Antiphospholipid Syndrome. Rheumatic Disease Clinics of North America, 2006, 32, 523-535.	0.8	7
140	The management of Sjögren's syndrome. Nature Clinical Practice Rheumatology, 2006, 2, 252-261.	3.2	110
141	Sjögren's syndrome: why autoimmune epithelitis?. Oral Diseases, 2006, 12, 523-532.	1.5	80
142	Preferential recognition of the phosphorylated major linear B-cell epitope of La/SSB 349-368aa by anti-La/SSB autoantibodies from patients with systemic autoimmune diseases. Clinical and Experimental Immunology, 2006, 144, 432-439.	1.1	33
143	Post-translational modifications of the major linear epitope 169?190aa of Ro60�kDa autoantigen alter the autoantibody binding. Clinical and Experimental Immunology, 2006, 146, 60-65.	1.1	21
144	Anti-LA/SSB antiidiotypic antibodies in maternal serum: A marker of low risk for neonatal lupus in an offspring. Arthritis and Rheumatism, 2006, 54, 2228-2234.	6.7	40

#	Article	IF	CITATIONS
145	Osteoarticular Manifestations of Antiphospholipid Syndrome. , 2006, , 127-139.		O
146	Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine,) Tj ETQq0 0	0 gB T /O	ve rl øck 10 Tf
147	The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjögren's syndrome (autoimmune epithelitis). Lupus, 2006, 15, 255-261.	0.8	81
148	Sjögren Syndrome. , 2006, , 401-416.		3
149	Autoimmunity and Coxsackievirus Infection in Primary Sjögren's Syndrome. Annals of the New York Academy of Sciences, 2005, 1050, 389-396.	1.8	23
150	Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein. Clinical and Experimental Immunology, 2005, 141, 148-154.	1.1	63
151	Salivary gland epithelial cell exosomes: A source of autoantigenic ribonucleoproteins. Arthritis and Rheumatism, 2005, 52, 1517-1521.	6.7	185
152	Recent advances in the management of ocular complications of sjögren's syndrome. Current Allergy and Asthma Reports, 2005, 5, 327-332.	2.4	22
153	The Risk of Lymphoma Development in Autoimmune Diseases. Archives of Internal Medicine, 2005, 165, 2337.	4.3	647
154	Clinical Manifestations and Early Diagnosis of Sjögren Syndrome. Archives of Internal Medicine, 2004, 164, 1275.	4.3	565
155	Central nervous system involvement in Sjogren's syndrome. Annals of the Rheumatic Diseases, 2004, 63, 616-620.	0.5	102
156	Sjogren's Syndrome. Autoimmunity, 2004, 37, 305-307.	1.2	30
157	Sjögren's syndrome associated with systemic lupus erythematosus: Clinical and laboratory profiles and comparison with primary Sjögren's syndrome. Arthritis and Rheumatism, 2004, 50, 882-891.	6.7	226
158	Evidence for coxsackievirus infection in primary Sjögren's syndrome. Arthritis and Rheumatism, 2004, 50, 2897-2902.	6.7	128
159	Immunologic factors in the pathogenesis of osteonecrosis. Orthopedic Clinics of North America, 2004, 35, 259-263.	0.5	30
160	The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. Clinica Chimica Acta, 2004, 340, $1-25$.	0.5	61
161	Lymphoproliferation in autoimmunity and Sjögren's syndrome. Current Rheumatology Reports, 2003, 5, 317-323.	2.1	42
162	Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: A prospective study by magnetic resonance imaging. Arthritis and Rheumatism, 2003, 48, 732-736.	6.7	128

#	Article	IF	CITATIONS
163	Calreticulin binds preferentially with B cell linear epitopes of Ro60â€∫kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies. Clinical and Experimental Immunology, 2003, 134, 143-150.	1.1	47
164	Idiotype–anti-idiotype circuit in non-autoimmune mice after immunization with the epitope and complementary epitope 289–308aa of La/SSB: implications for the maintenance and perpetuation of the anti-La/SSB response. Journal of Autoimmunity, 2003, 21, 17-26.	3.0	35
165	Lupus nephritis: treatment with mycophenolate mofetil. British Journal of Rheumatology, 2003, 43, 377-380.	2.5	89
166	Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Annals of the Rheumatic Diseases, 2002, 61, 554-558.	0.5	4,586
167	Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study. Annals of the Rheumatic Diseases, 2002, 61, 398-404.	0.5	60
168	Unmasking the Anti-La/SSB Response in Sera From Patients With Sjogren's Syndrome by Specific Blocking of Anti-idiotypic Antibodies to La/SSB Antigenic Determinants. Molecular Medicine, 2002, 8, 293-305.	1.9	48
169	Characterization of the cysteine-rich secretory protein 3 gene as an early-transcribed gene with a putative role in the pathophysiology of Sj�gren's syndrome. Arthritis and Rheumatism, 2002, 46, 215-222.	6.7	27
170	Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis and Rheumatism, 2002, 46, 741-747.	6.7	410
171	2-chloro-2?-deoxyadenosine in the treatment of Sj�gren's syndrome-associated B cell lymphoproliferation. Arthritis and Rheumatism, 2002, 46, 2248-2249.	6.7	21
172	CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation. Clinical and Experimental Immunology, 2002, 127, 386-392.	1.1	91
173	The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clinical and Experimental Immunology, 2002, 128, 562-568.	1.1	176
174	Therapy of Sjögren's syndrome. Seminars in Immunopathology, 2001, 23, 131-145.	4.0	19
175	Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sjögren's syndrome: high expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells. Clinical and Experimental Immunology, 2001, 124, 126-133.	1.1	77
176	?Lymphoid? chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sj�gren's syndrome patients: Possible participation in lymphoid structure formation. Arthritis and Rheumatism, 2001, 44, 408-418.	6.7	165
177	Functional Expression of a Costimulatory B7.2 (CD86) Protein on Human Salivary Gland Epithelial Cells that Interacts with the CD28 Receptor, but Has Reduced Binding to CTLA4. Journal of Immunology, 2001, 166, 3107-3113.	0.4	83
178	Sjögren's syndrome: current concepts. Advances in Internal Medicine, 2001, 47, 191-217.	0.9	33
179	Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjogren Syndrome. Medicine (United States), 2000, 79, 241-249.	0.4	170
180	Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney International, 2000, 57, 258-264.	2.6	186

#	Article	IF	CITATIONS
181	Study of antibody and T cell responses in rabbits immunized with synthetic human B cell epitope analogues of La (SSB) autoantigen. Clinical and Experimental Immunology, 2000, 121, 551-556.	1.1	24
182	Dental and periodontal status of Sjögren's syndrome. Journal of Clinical Periodontology, 2000, 27, 231-235.	2.3	68
183	Clinical evolution, and morbidity and mortalityof primary Sjögren's syndrome. Seminars in Arthritis and Rheumatism, 2000, 29, 296-304.	1.6	433
184	B-Cell Epitope Mapping of DNA Topoisomerase I Defines Epitopes Strongly Associated with Pulmonary Fibrosis in Systemic Sclerosis. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 344-351.	1.4	30
185	Neuroendocrine Manifestations in Sj \tilde{A} ¶gren's Syndrome: Relation to the Neurobiology of Stress. Annals of the New York Academy of Sciences, 2000, 917, 797-808.	1.8	24
186	Mixed Cryoglobulinemia in HIV-1 Infection: The Role of HIV-1. Annals of Internal Medicine, 1999, 130, 226.	2.0	56
187	Lung involvement in primary Sjogren's syndrome is mainly related to the small airway disease. Annals of the Rheumatic Diseases, 1999, 58, 61-64.	0.5	178
188	Lymphoma development in Sj�gren's syndrome: Novel p53 mutations. Arthritis and Rheumatism, 1999, 42, 1466-1472.	6.7	84
189	Malignant lymphoma in primary Sj�gren's syndrome: A multicenter, retrospective, clinical study by the European concerted action on Sj�gren's syndrome. Arthritis and Rheumatism, 1999, 42, 1765-1772.	6.7	468
190	Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sj�gren's syndrome. Arthritis and Rheumatism, 1999, 42, 229-239.	6.7	122
191	Autoantibodies to La/SSB in Patients with Primary Sjögren's Syndrome (pSS) are Associated with Upregulation of La/SSB mRNA in Minor Salivary Gland Biopsies (MSGs). Journal of Autoimmunity, 1999, 13, 429-434.	3.0	29
192	Sjögren's Syndrome. Advances in Experimental Medicine and Biology, 1999, , 127-134.	0.8	50
193	Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis. Journal of Clinical Immunology, 1998, 18, 380-391.	2.0	36
194	Modes of epithelial cell death and repair in Sj \tilde{A} ¶gren's syndrome (SS). Clinical and Experimental Immunology, 1998, 114, 485-490.	1.1	102
195	Prevalence of Sjogren's-like syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunopathology. Rheumatology, 1998, 37, 691-695.	0.9	71
196	Pregnancy outcome and anti-Ro/SSA in autoimmune diseases: a retrospective cohort study. Rheumatology, 1998, 37, 740-745.	0.9	42
197	Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic. Journal of Rheumatology, 1998, 25, 886-91.	1.0	16
198	Prevalence of Sjogren's syndrome in a closed rural community. Annals of the Rheumatic Diseases, 1997, 56, 521-525.	0.5	139

#	Article	IF	CITATIONS
199	Grand rounds from lupus centersâ€"Edited by R Lahita. Lupus, 1997, 6, 353-357.	0.8	O
200	Title is missing!. International Journal of Peptide Research and Therapeutics, 1997, 4, 447-454.	0.1	1
201	The PPGMRPP repetitive epitope of the Sm autoantigen: Antigenic specificity induced by conformational changes. Application of the Sequential Oligopeptide Carriers (SOCs). International Journal of Peptide Research and Therapeutics, 1997, 4, 447-454.	0.1	4
202	The uncertain role of immunosuppressive agents in Sjogren's syndrome. Cleveland Clinic Journal of Medicine, 1997, 64, 523-526.	0.6	17
203	Sjögren's syndrome therapy: future directions. Journal of rheumatology Supplement, The, 1997, 50, 33-4.	2.2	2
204	Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis and Rheumatism, 1996, 39, 767-772.	6.7	230
205	Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjogren's Syndrome Annals of the Rheumatic Diseases, 1996, 55, 116-121.	0.5	400
206	Immunoreactivity and conformation of the Pâ€Pâ€Câ€Mâ€Râ€Pâ€P repetitive epitope of the Sm autoantigen. International Journal of Peptide and Protein Research, 1996, 48, 319-327.	0.1	22
207	Antimalarials in Sjögren's syndromethe Greek experience. Lupus, 1996, 5 Suppl 1, S28-30.	0.8	7
208	Methotrexate in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 1996, 14, 555-8.	0.4	88
209	CYTOKINE mRNA EXPRESSION IN THE LABIAL SALIVARY GLAND TISSUES FROM PATIENTS WITH PRIMARY SJĶGREN'S SYNDROME. Rheumatology, 1995, 34, 326-333.	0.9	154
210	Cutaneous Lymphocytic Vasculopathy in Lymphoproliferative Disorders-A Paraneoplastic Lymphocytic Vasculitis of the Skin. Leukemia and Lymphoma, 1995, 16, 477-482.	0.6	33
211	LIVER INVOLVEMENT IN PRIMARY SJ×GREN'S SYNDROME. Rheumatology, 1994, 33, 745-748.	0.9	129
212	Connective Tissue Diseases: One Disease or Many?. Lupus, 1994, 3, 5-10.	0.8	9
213	The European Community Study Group on diagnostic criteria for Sjogren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjogren's syndrome Annals of the Rheumatic Diseases, 1994, 53, 637-647.	0.5	298
214	Obstetric and gynaecological profile in patients with primary Sjogren's syndrome Annals of the Rheumatic Diseases, 1994, 53, 569-573.	0.5	73
215	Sjöc;gren's Syndrome: Autoimmune Epithelitis. Clinical Immunology and Immunopathology, 1994, 72, 162-165.	2.1	385
216	Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European community. Arthritis and Rheumatism, 1993, 36, 340-347.	6.7	1,477

#	Article	IF	CITATIONS
217	Autoantibodies to hmg-17 nucleosomal protein in autoimmune rheumatic diseases. Arthritis and Rheumatism, 1993, 36, 955-961.	6.7	28
218	Systemic Lupus Erythematosus in Greece. Clinical Features, Evolution and Outcome: a Descriptive Analysis of 292 Patients. Lupus, 1993, 2, 303-312.	0.8	92
219	Molecular analysis of HLA class II genes in primary sjo¨gren's syndrome. Human Immunology, 1993, 36, 235-242.	1.2	42
220	PATIENTS WITH ANTICENTROMERE ANTIBODIES, CLINICAL FEATURES, DIAGNOSES AND EVOLUTION. Rheumatology, 1993, 32, 297-301.	0.9	64
221	Is central nervous system involvement a systemic manifestation of primary Sjögren's syndrome?. Rheumatic Disease Clinics of North America, 1993, 19, 909-12.	0.8	10
222	HLA Class ii sequence polymorphisms and susceptibility to rheumatoid arthritis in greeks. the hla–drβ shared-epitope hypothesis accounts for the disease in only a minority of greek patients. Arthritis and Rheumatism, 1992, 35, 749-755.	6.7	107
223	Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies. Medical and Pediatric Oncology, 1992, 20, 26-31.	1.0	29
224	Lymphoma in Sjogren's syndrome. Medical and Pediatric Oncology, 1992, 20, 279-283.	1.0	49
225	Histologic lesion in labial salivary glands of patients with systemic lupus erythematosus. Oral Surgery, Oral Medicine, and Oral Pathology, 1991, 72, 208-212.	0.6	17
226	Nephrocalcinosis in Sjögren's syndrome: a late sequela of renal tubular acidosis. Journal of Internal Medicine, 1991, 230, 187-191.	2.7	61
227	T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjögren's syndrome. Journal of Rheumatology, 1991, 18, 210-4.	1.0	83
228	Anti-Ro (SSA)/La (SSB) antibodies and Sjögren's syndrome. Clinical Rheumatology, 1990, 9, 123-131.	1.0	34
229	Intravenous pulse cyclophosphamide therapy in myositis and Sjögren's syndrome. Arthritis and Rheumatism, 1990, 33, 1579-1581.	6.7	33
230	Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology, 1990, 11, 730-734.	3.6	163
231	Association of serum IgM kappa monoclonicity in patients with Sjogren's syndrome with an increased proportion of kappa positive plasma cells infiltrating the labial minor salivary glands Annals of the Rheumatic Diseases, 1990, 49, 929-931.	0.5	33
232	New insights into the physiopathology of primary Sjögren's syndrome. Annales De Médecine Interne, 1990, 141, 53-6.	0.2	0
233	Raynaud's phenomenon in primary SjĶgren's syndrome. Journal of Rheumatology, 1990, 17, 618-20.	1.0	41
234	Immunopathogenesis of sjogren's syndrome: "Facts and fancy― Autoimmunity, 1989, 5, 17-24.	1.2	21

#	Article	IF	CITATIONS
235	IX Eular Workshop for Rheumatology Research. Clinical Rheumatology, 1989, 8, 118-172.	1.0	1
236	Sjögren's syndrome and the gut. Bailliere's Clinical Rheumatology, 1989, 3, 357-370.	1.0	11
237	Personality structure disturbances and psychiatric manifestations in primary Sjögren's syndrome. Journal of Autoimmunity, 1989, 2, 489-493.	3.0	25
238	Sj \tilde{A} ¶gren's syndrome in rheumatoid arthritis and progressive systemic sclerosis. A comparative study. Clinical and Experimental Rheumatology, 1989, 7, 203-5.	0.4	29
239	PREVALENCE OF PRIMARY SJ×GREN'S SYNDROME IN AN ELDERLY POPULATION. Rheumatology, 1988, 27, 123-127.	0.9	114
240	Clinical implications of the presence of anti-Ro(SSA) antibodies in patients with rheumatoid arthritis. Journal of Autoimmunity, 1988, 1, 381-388.	3.0	30
241	CD5-expressing B lymphocytes in the blood and salivary glands of patients with primary SjA¶gren's syndrome. Journal of Autoimmunity, 1988, 1, 185-194.	3.0	85
242	SJÃ-GREN'S SYNDROME: A HUMAN MODEL OF AUTOIMMUNITY AND MALIGNANCY. Rheumatology, 1988, 27, 253-257.	0.9	3
243	Immunopathogenesis of Sjögren's syndrome. Israel Journal of Medical Sciences, 1988, 24, 737-9.	0.1	1
244	Vasculitis in Primary Sjögren's Syndrome: Histologic Classification and Clinical Presentation. American Journal of Clinical Pathology, 1987, 88, 26-31.	0.4	91
245	High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clinical and Experimental Immunology, 1987, 69, 557-65.	1.1	250
246	Secondary Sjögren's syndrome in rheumatoid arthritis. Journal of Rheumatology, 1987, 14, 1098-103.	1.0	71
247	Hand Radiographic Changes in Patients with Primary and Secondary Sjögren's Syndrome. Scandinavian Journal of Rheumatology, 1986, 15, 333-339.	0.6	21
248	HLA-DR expression by labial minor salivary gland tissues in Sjogren's syndrome Annals of the Rheumatic Diseases, 1986, 45, 677-683.	0.5	111
249	Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study Annals of the Rheumatic Diseases, 1986, 45, 732-735.	0.5	73
250	Preliminary diagnostic criteria for Sjögren's syndrome. Scandinavian Journal of Rheumatology, Supplement, 1986, 61, 22-5.	0.2	46
251	Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects Annals of the Rheumatic Diseases, 1985, 44, 215-219.	0.5	47
252	Demonstration and identification of monoclonal proteins in the urine of patients with Sjogren's syndrome Annals of the Rheumatic Diseases, 1985, 44, 109-112.	0.5	61

#	Article	IF	CITATIONS
253	HLA DR alloantigens in different subsets of patients with Sjogren's syndrome and in family members Annals of the Rheumatic Diseases, 1983, 42, 533-536.	0.5	62
254	Interferon and autoimmunity. Clinical and Experimental Rheumatology, 1983, 1, 81-4.	0.4	4
255	High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome. Journal of Immunology, 1983, 130, 2663-5.	0.4	51
256	Detection of anti-interferon antibodies in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 1983, 1, 133-5.	0.4	14
257	Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis and Rheumatism, 1982, 25, 396-400.	6.7	161
258	The clinical picture of primary Sjögren's syndrome: a retrospective study. Journal of Rheumatology, 1982, 9, 685-90.	1.0	81
259	Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary sjögren's syndrome. Arthritis and Rheumatism, 1981, 24, 577-584.	6.7	104
260	Sjögren's Syndrome (Sicca Syndrome): Current Issues. Annals of Internal Medicine, 1980, 92, 212.	2.0	463
261	Correlative histologic and serologic findings of sicca syndrome in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1980, 23, 36-40.	6.7	67
262	Sicca-like syndrome in type v hyperlipoproteinemia. Arthritis and Rheumatism, 1980, 23, 114-118.	6.7	22
263	Immunization of patients with sj \tilde{A} gren's syndrome with pneumococcal polysaccharide vaccine. Arthritis and Rheumatism, 1980, 23, 1294-1298.	6.7	29
264	Thyroid disease in sjögren's syndrome. Arthritis and Rheumatism, 1980, 23, 1326-1329.	6.7	104
265	THE ROLE OF INTERFERON IN IMMEDIATE HYPERSENSITIVITY AND AUTOIMMUNE DISEASES. Annals of the New York Academy of Sciences, 1980, 350, 21-32.	1.8	34
266	Immunoregulation in Sjögren's Syndrome. Journal of Clinical Investigation, 1980, 65, 519-528.	3.9	61
267	Genetic Differences between Primary and Secondary Sicca Syndrome. New England Journal of Medicine, 1979, 301, 761-763.	13.9	161
268	CBA/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice Journal of Experimental Medicine, 1979, 150, 31-43.	4.2	71
269	Primary amyloidosis resembling sicca syndrome. Arthritis and Rheumatism, 1979, 22, 932-934.	6.7	48
270	Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. American Journal of Medicine, 1979, 66, 733-736.	0.6	196

#	ARTICLE	IF	CITATIONS
271	Immune Interferon in the Circulation of Patients with Autoimmune Disease. New England Journal of Medicine, 1979, 301, 5-8.	13.9	849
272	Immune complex glomerulonephritis in sicca syndrome. American Journal of Medicine, 1978, 64, 955-960.	0.6	112
273	Increased Risk of Lymphoma in Sicca Syndrome. Annals of Internal Medicine, 1978, 89, 888.	2.0	914
274	Sjögren's Syndrome Associated with HLA-Dw3. New England Journal of Medicine, 1977, 296, 895-897.	13.9	184
275	Sjögren-Type Syndrome After Allogeneic Bone-Marrow Transplantation. Annals of Internal Medicine, 1977, 87, 703.	2.0	204
276	Association of Sjögren's syndrome with HLA-B8. Arthritis and Rheumatism, 1976, 19, 883-886.	6.7	79